Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC HF 2025
FINAL_VELOCITY_LBCT_May14.pdf
ESC HF_vericiguat_clinical characteristics and outcomes_v3 (14 Apr).pdf
ESC HF_vericiguat_dosing titration and cox model_15 April 2025.pdf
ePoster_HFA-Congress_2025_ROVER_Adh-Pers_v02 (2).pdf
ePoster_HFA-Congress_2025_ROVER_ACM-HFH_v03 (1).pdf
Poster+Belgrado_Diagnosis+management+HFrEF+patient_v0.4_20250408 (1).pdf
25-04-22_VICTOR Regional BL_POS v2.0.pdf
Poster+Belgrado_Post+discharge+follow+up+HFrEF_v1.0_20250407 (4).pdf
0518_Mitchell_ESC-HF Diagnostic Delays_poster_21Apr2025_FINAL.pdf
0518_Obici_2025Apr17_ESC-HF2025_ACM CVM cause poster_v7.0.pdf
0520_Ducharme_2025Apr17_ESC-HF2025_sTTR wt vs variant oral_v9.0.pdf
0518_Alexander_2025Apr14_ESC-HF2025 AF AFL TEAE poster_v6.0.pdf
0517_Judge_ESC HF TAF Poster_21APR2025_FINAL.pdf
0518_Fontana_2025Apr17_ESC-HF2025_6MWD KCCQ poster_v7.0.pdf
0518_Fontana_2025Apr17_ESC-HF2025_ACM CVH NT-proBNP_v8.0_0.pdf
© 2025 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0006-1
